科兴、卫星 V、阿斯利康和 Coviran Barekat 疫苗接种后第一周内的反应原性：来自伊朗主动疫苗监测系统的发现。
Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system.
机构信息
Clinical Research Development Unit, Bahar Hospital, Shahroud University of Medical Science, Shahroud, Iran.
Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.
出版信息
BMC Infect Dis. 2023 Mar 10;23(1):150. doi: 10.1186/s12879-023-08103-4.
BACKGROUND
This study aimed to evaluate the reactogenicity effects of COVID-19 vaccines, used in Iran.
METHODS
At least 1000 people were followed up with phone calls or self-report in a mobile application within 7 days after vaccination. Local and systemic reactogenicities were reported overall and by subgroups.
RESULTS
The presence of one or more local and systemic adverse effects after the first dose of vaccines was 58.9% [(95% Confidence Intervals): 57.5-60.3)] and 60.5% (59.1-61.9), respectively. These rates were reduced to 53.8% (51.2-55.0) and 50.8% (48.8-52.7) for the second dose. The most common local adverse effect reported for all vaccines was pain in the injection site. During the first week after the first dose of vaccines, the frequency of the pain for Sinopharm, AZD1222, Sputnik V, and Barekat was 35.5%, 86.0%, 77.6%, and 30.9%, respectively. The same rates after the second dose were 27.3%, 66.5%, 63.9%, and 49.0%. The most common systemic adverse effect was fatigue. In the first dose, it was 30.3% for Sinopharm, 67.4% for AZD1222, 47.6% for Sputnik V, and 17.1% for Barekat. These rates were reduced to 24.6%, 37.1%, 36.5%, and 19.5%, in the second dose of vaccines. AZD1222 had the highest local and systemic adverse effects rates. The odds ratio of local adverse effects of the AZD1222 vaccine compared to the Sinopharm vaccine were 8.73 (95% CI 6.93-10.99) in the first dose and 4.14 (95% CI 3.32-5.17) in the second dose. Barekat and Sinopharm had the lowest frequency of local and systemic adverse effects. Compared to Sinopharm, systemic adverse effects were lower after the first dose of Barekat (OR = 0.56; 95% CI 0.46-0.67). Reactogenicity events were higher in women and younger people. Prior COVID-19 infection increased the odds of adverse effects only after the first dose of vaccines.
CONCLUSIONS
Pain and fatigue were the most common reactogenicities of COVID-19 vaccination. Reactogenicities were less common after the second dose of the vaccines. The adverse effects of AZD1222 were greater than those of other vaccines.
背景
本研究旨在评估在伊朗使用的 COVID-19 疫苗的不良反应。
方法
至少有 1000 人在接种疫苗后 7 天内通过电话或移动应用程序进行自我报告。总体和亚组报告局部和全身不良反应。
结果
首次接种疫苗后出现 1 种或多种局部和全身不良反应的比例分别为 58.9%（95%置信区间：57.5-60.3）和 60.5%（59.1-61.9）。第二次接种后，这些比例分别降至 53.8%（51.2-55.0）和 50.8%（48.8-52.7）。所有疫苗中报告的最常见局部不良反应是注射部位疼痛。在首次接种疫苗后的第一周，国药、阿斯利康、卫星 V 和巴雷克特的疼痛频率分别为 35.5%、86.0%、77.6%和 30.9%。第二次接种后的相同比例分别为 27.3%、66.5%、63.9%和 49.0%。最常见的全身不良反应是疲劳。在首次接种疫苗时，国药、阿斯利康、卫星 V 和巴雷克特的疲劳发生率分别为 30.3%、67.4%、47.6%和 17.1%。第二次接种疫苗后，这些比例分别降至 24.6%、37.1%、36.5%和 19.5%。阿斯利康的局部和全身不良反应发生率最高。与国药相比，首次接种时阿斯利康疫苗的局部不良反应的优势比为 8.73（95%CI 6.93-10.99），第二次接种时为 4.14（95%CI 3.32-5.17）。巴雷克特和国药的局部和全身不良反应发生率最低。与国药相比，首次接种巴雷克特后全身不良反应发生率较低（OR=0.56；95%CI 0.46-0.67）。女性和年轻人的不良反应发生率更高。既往感染 COVID-19 仅在首次接种疫苗后增加不良反应的几率。
结论
疼痛和疲劳是 COVID-19 疫苗接种最常见的不良反应。第二次接种疫苗后不良反应较少。阿斯利康疫苗的不良反应大于其他疫苗。
Zotero 插件